News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
